Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242134 | 0.79 | KDM4E (0.38) | ALDH1A1GAA | |
| SCHEMBL28330955 | 0.77 | ALDH1A1 (0.43) | CYP2A6MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL14058825 | 0.71 | — | — | |
| SCHEMBL1984415 | 0.69 | — | — | |
| SCHEMBL8656230 | 0.69 | KDM4E (0.31) | GAA | |
| SCHEMBL10437514 | 0.67 | ALDH1A1 (0.37) | ALDH1A1GAA | |
| SCHEMBL6841722 | 0.67 | CHEK1 (0.34) | MEN1ALDH1A1KMT2ATDP1GAA | |
| SCHEMBL5556616 | 0.67 | — | — | |
| SCHEMBL8655726 | 0.67 | KDM4E (0.30) | GAA | |
| SCHEMBL625866 | 0.67 | CA1 (0.40) | CYP2A6MEN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656351-B1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7288658-B2 | Process for preparation of pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1656351-A1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005014549-A1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20050014792-A1 | Process for preparation of pyridine derivatives | ROCHE PALO ALTO LLC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014792-A1 | Process for preparation of pyridine derivatives | NOX3, KMO, PBK | CYP2A6 502/4885CYP2A13 275/4885MEN1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.